Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
39.90 K
Value Traded
19.88 K
Short % Float
-
Days to Cover
1.0
-16.02%Week
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
17.78 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
17.66 M
Total Shares
37.95 M
Float Shares
-
Insiders
-
Institutions
-
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
PETV Catalyst Timeline
Dated clinical, regulatory and corporate events for PetVivo Holdings, Inc.
Past FDA Catalysts and PDUFA Decisions
How PETV actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
PetVivo Holdings, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every PETV program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| A.L. Sarroff Fund, LLC10% Owner | Buy | 3,000 10,546,617 held | $0.70 | 10/16/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PETV
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in PETV for Q2 2026. | ||||
Ownership Trends
PETV Short Interest
Shares sold short, counted twice a month.
-
Short % of Float
of tradable shares sold short
2.6K
Shares Sold Short
-79.3% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
8.0K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PETV ranks across every disease it competes in
Competitive Position is a premium feature
See how PETV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPETV News
-PETV
Nov 11, 2026▼ -16.4%today
PETVIVO HOLDINGS TO FILE QUARTERLY REPORT ON NOVEMBER 13, 2026; WELCOMES SHAREHOLDER QUESTIONS AND DIALOGUE
PetVivo Holdings, Inc. announced it will file its Quarterly Report on Form 10-Q on November 13, 2026. The company will communicate financial results through SEC filings without separate press releases or earnings calls. Shareholders are encouraged to engage with management for discussions and feedback.
Read more →-PETV
Oct 15, 2026PETVIVO ANNOUNCES RELEASE OF TWO REASEARCH ABSTRACTS AND UPCOMING CONFERENCE PRESENTATIONS ON OSTEOARTHRITIS IN RHESUS MACAQUES
PetVivo Holdings announced two research abstracts on its hydrogel therapy for osteoarthritis in rhesus macaques. The studies showed improved mobility and minimal inflammatory response following treatment with Spryng® with OsteoCushion® Technology. These findings will be presented at three upcoming veterinary conferences, indicating potential for further research and application.
Read more →-PETV
Aug 20, 2026PETVIVO HOLDINGS ANNOUNCES NAME CHANGE OF HUMAN SUBSIDIARY TO SOMATRIX TECHNOLOGIES, INC. AND EXPANDS FOCUS ON HUMAN HEALTH INNOVATION
PetVivo Holdings announced the renaming of its subsidiary Cosmeta Corp. to Somatrix Technologies, Inc., focusing on human health innovations. Somatrix aims to develop advanced biomaterials for therapeutic applications in both human and veterinary health. The company believes these innovations can enhance patient outcomes and address unmet medical needs across various therapeutic areas.
Read more →-PETV
Jul 28, 2026PETVIVO HOLDINGS ANNOUNCES TERMINATION AND SETTLEMENT AGREEMENT WITH VETSTEM
PetVivo Holdings announced a Termination and Settlement Agreement with VetStem, effective July 24, 2026. This agreement resolves all outstanding matters related to the PrecisePRP® product line and allows PetVivo to focus on its proprietary technologies. The company will make a total payment of $75,000 and return remaining inventory to VetStem.
Read more →About PetVivo Holdings, Inc.
BIOPHARMAWATCH ELITE
Trade the next PETV catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime